GeneDx Holdings Corp. – NASDAQ:WGS
GeneDx Holdings Corp. stock price today
$124.47
+46.42
+59.47%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
GeneDx Holdings Corp. stock price monthly change
+137.96%
month
GeneDx Holdings Corp. stock price quarterly change
+137.96%
quarter
GeneDx Holdings Corp. stock price yearly change
+2600.69%
year
GeneDx Holdings Corp. key metrics
Market Cap | 2.07B |
Enterprise value | 65.19M |
P/E | -0.17 |
EV/Sales | 0.28 |
EV/EBITDA | -0.22 |
Price/Sales | 0.50 |
Price/Book | 0.46 |
PEG ratio | N/A |
EPS | -5.25 |
Revenue | 221.84M |
EBITDA | -81.95M |
Income | -135.01M |
Revenue Q/Q | 44.69% |
Revenue Y/Y | -0.91% |
Profit margin | -121.42% |
Oper. margin | -198.49% |
Gross margin | -0.53% |
EBIT margin | -198.49% |
EBITDA margin | -36.94% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGeneDx Holdings Corp. stock price history
GeneDx Holdings Corp. stock forecast
GeneDx Holdings Corp. financial statements
Average Price Target
$49.67
Potential downside: -60.09%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 48.70M | -46.71M | -95.92% |
|---|---|---|---|
| Sep 2023 | 53.30M | -42.28M | -79.33% |
| Dec 2023 | 57.41M | -25.77M | -44.89% |
| Mar 2024 | 62.42M | -20.23M | -32.42% |
| Jun 2023 | 476390000 | 180.27M | 37.84% |
|---|---|---|---|
| Sep 2023 | 417285000 | 163.02M | 39.07% |
| Dec 2023 | 473674000 | 245.65M | 51.86% |
| Mar 2024 | 394528000 | 187.31M | 47.48% |
| Jun 2023 | -53.50M | -11.27M | 7.38M |
|---|---|---|---|
| Sep 2023 | -40.97M | -27.37M | -911K |
| Dec 2023 | -29.85M | -4.86M | 47.10M |
| Mar 2024 | -16.41M | 843K | -438K |
GeneDx Holdings Corp. alternative data
| Aug 2023 | 1,100 |
|---|---|
| Sep 2023 | 1,100 |
| Oct 2023 | 1,100 |
| Nov 2023 | 1,100 |
| Dec 2023 | 1,100 |
| Jan 2024 | 1,100 |
| Feb 2024 | 1,100 |
| Mar 2024 | 1,000 |
| Apr 2024 | 1,000 |
| May 2024 | 1,000 |
| Jun 2024 | 1,000 |
| Jul 2024 | 1,000 |
GeneDx Holdings Corp. other data
18.42%
-18.43%
of WGS is owned by hedge funds
47
-32
62.23M
-78.09M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 298 |
| Mar 2024 | 40900 | 18567 |
| Apr 2024 | 0 | 7429 |
| May 2024 | 260000 | 0 |
| Jun 2024 | 130000 | 3809 |
| Jul 2024 | 0 | 576467 |
| Aug 2024 | 0 | 337592 |
| Sep 2024 | 0 | 17932 |
| Oct 2024 | 0 | 868228 |
| Nov 2024 | 0 | 261556 |
| Dec 2024 | 0 | 19290 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | STUELAND KATHERINE director, officer.. | Restricted Stock Unit | 18,750 | N/A | N/A | ||
Option | STUELAND KATHERINE director, officer.. | Class A Common Stock | 18,750 | N/A | N/A | ||
Sale | STUELAND KATHERINE director, officer.. | Class A Common Stock | 10,501 | $76.75 | $805,994 | ||
Option | FEELEY KEVIN officer: CHIEF FINANCIAL OFFICER | Restricted Stock Unit | 7,197 | N/A | N/A | ||
Option | FEELEY KEVIN officer: CHIEF FINANCIAL OFFICER | Class A Common Stock | 7,197 | N/A | N/A | ||
Sale | FEELEY KEVIN officer: CHIEF FINANCIAL OFFICER | Class A Common Stock | 3,728 | $76.75 | $286,139 | ||
Option | FEELEY KEVIN officer: CHIEF FINANCIAL OFFICER | Class A Common Stock | 2,462 | N/A | N/A | ||
Option | STUELAND KATHERINE director, officer.. | Class A Common Stock | 6,547 | N/A | N/A | ||
Sale | STUELAND KATHERINE director, officer.. | Class A Common Stock | 3,661 | $76.37 | $279,598 | ||
Option | STUELAND KATHERINE director, officer.. | Restricted Stock Unit | 6,547 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q1 2024 29 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 20 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 4 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 12 Aug 2023 | Q2 2023 Earnings Call Transcript |
GeneDx: Strong Testing Volume And An Invaluable Genomic Database
GeneDx: Strong Fundamentals Intact As Market Misreads Test Volume Dip
GeneDx: Time To Buy The Dip
GeneDx: Strengthening Leadership In Genomic Diagnostics
GeneDx Holdings: A Phenomenal Comeback With More Room To Run
Best-Performing Stocks Of 2024
GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
OPKO Health's Future After Merck Deal: Bright Or Uncertain
23andMe Holding: At Risk Of Becoming Irrelevant
-
What's the price of GeneDx Holdings Corp. stock today?
One share of GeneDx Holdings Corp. stock can currently be purchased for approximately $124.47.
-
When is GeneDx Holdings Corp.'s next earnings date?
Unfortunately, GeneDx Holdings Corp.'s (WGS) next earnings date is currently unknown.
-
Does GeneDx Holdings Corp. pay dividends?
No, GeneDx Holdings Corp. does not pay dividends.
-
How much money does GeneDx Holdings Corp. make?
GeneDx Holdings Corp. has a market capitalization of 2.07B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 13.69% to 202.57M US dollars.
-
What is GeneDx Holdings Corp.'s stock symbol?
GeneDx Holdings Corp. is traded on the NASDAQ under the ticker symbol "WGS".
-
What is GeneDx Holdings Corp.'s primary industry?
Company operates in the Healthcare sector and Medical - Healthcare Information Services industry.
-
How do i buy shares of GeneDx Holdings Corp.?
Shares of GeneDx Holdings Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does GeneDx Holdings Corp. have?
As Jul 2024, GeneDx Holdings Corp. employs 1,000 workers.
-
When GeneDx Holdings Corp. went public?
GeneDx Holdings Corp. is publicly traded company for more then 4 years since IPO on 4 Nov 2020.
-
What is GeneDx Holdings Corp.'s official website?
The official website for GeneDx Holdings Corp. is genedx.com.
-
Where are GeneDx Holdings Corp.'s headquarters?
GeneDx Holdings Corp. is headquartered at North Tower, Stamford, CT.
-
How can i contact GeneDx Holdings Corp.?
GeneDx Holdings Corp.'s mailing address is North Tower, Stamford, CT and company can be reached via phone at +800 2986470.
-
What is GeneDx Holdings Corp. stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for GeneDx Holdings Corp. in the last 12 months, the avarage price target is $49.67. The average price target represents a -60.09% change from the last price of $124.47.
GeneDx Holdings Corp. company profile:
GeneDx Holdings Corp.
genedx.comExchange:
NASDAQ
Full time employees:
1,000
Industry:
Medical - Healthcare Information Services
Sector:
Healthcare
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
North Tower
Stamford, CT 06902
Stamford, CT 06902
CIK: 0001818331
ISIN: US81663L2007
CUSIP: 81663L200
